Valeria Tomati

Genoa, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment.

Vanzacaftor-Tezacaftor as an alternative therapeutic resource for the ETI-Resistant L467F-F508del Allele: Ex vivo prediction and exploratory clinical assessment.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 05, 2026

Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant.

Alternative splicing and residual function potentially expand the therapeutic landscape of the CFTRdele2ins182 variant.

Journal: PloS one

Published: July 09, 2025

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.

Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR.

Journal: Frontiers in pharmacology

Published: July 07, 2025

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

In silico, in vitro and ex vivo characterization of cystic fibrosis transmembrane conductance regulator pathogenic variants localized in the fourth intracellular loop and their rescue by modulators.

Journal: British journal of pharmacology

Published: March 14, 2025

Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators.

Pharmacological rescue of the G85E CFTR variant by preclinical and approved modulators.

Journal: Frontiers in pharmacology

Published: September 10, 2024

Sources of biases in the in vitro testing of nanomaterials: the role of the biomolecular corona.

Sources of biases in the in vitro testing of nanomaterials: the role of the biomolecular corona.

Journal: Nanoscale horizons

Published: April 02, 2024

Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS).

Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS).

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: February 28, 2024

SUMOylation Inhibition Enhances Protein Transcription under CMV Promoter: A Lesson from a Study with the F508del-CFTR Mutant.

SUMOylation Inhibition Enhances Protein Transcription under CMV Promoter: A Lesson from a Study with the F508del-CFTR Mutant.

Journal: International journal of molecular sciences

Published: December 13, 2023

De novo variants in DENND5B cause a neurodevelopmental disorder.

De novo variants in DENND5B cause a neurodevelopmental disorder.

Journal: American journal of human genetics

Published: August 31, 2023

Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5.

Innovative Strategy toward Mutant CFTR Rescue in Cystic Fibrosis: Design and Synthesis of Thiadiazole Inhibitors of the E3 Ligase RNF5.

Journal: Journal of medicinal chemistry

Published: July 13, 2023

The combination elexacaftor/tezacaftor/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner.

The combination elexacaftor/tezacaftor/ivacaftor (ETI) modulates the de novo synthethic pathway of ceramides in a genotype-independent manner.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: March 01, 2023

Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators.

Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators.

Journal: International journal of molecular sciences

Published: February 27, 2023

Showing 1-12 of 40

Last Updated: 09/26/2026